Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Get your full text copy in PDF

CD95 rs1800682A/G Variant and Tumor Risk in Asians: Evidence from a Meta-Analysis of 36 Case-Control Studies Containing 22 438 Samples

Cheng Jin, Xiaomin Wu, Yuanlong Gu, Fenglai Yuan, Qinghai Ye, Feng Dai, Lijie Zhu, Yuanyuan Mi

(Department of Hepatobiliary Pancreatic Center, Third Affiliated Hospital of Nantong University, Wuxi, Jiangsu, China (mainland))

Med Sci Monit 2015; 21:630-637

DOI: 10.12659/MSM.892547

Abstract: Background: The CD95 gene plays a key role in regulating cell growth and tumor genesis. To date, several publications have focused on the CD95 rs1800682A/G site polymorphism and various types of tumors in Asians; however, this association is still controversial and obscure. Therefore, a meta-analysis combined with all publications to clarify this association is necessary.
Material/Methods: A search in the PubMed and SinoMed databases was performed to detect all relevant included publications. Odds ratio (OR) and 95% confidence intervals (CI) revealed association strengths.
Results: Overall, 36 case-control studies were chosen based on the search criteria. There was no association of the CD95 rs1800682A/G site polymorphism with tumor risk in total and ethnicity subgroup analysis. However, further stratified analysis in the cancer subgroup revealed weakly significant associations in hepatocellular carcinoma (AA+AG vs. GG: OR=0.93, 95% CI=0.87–0.99, P=0.035; AG vs. GG: OR=0.89, 95% CI=0.80–0.99, P=0.036).
Conclusions: The CD95 rs1800682A/G site polymorphism may be associated with hepatocellular carcinoma susceptibility. Further large-scale and well-designed studies regarding tumor types and ethnicities are still required to confirm our results.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree